Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...
Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...
—Based on the findings from a recent study, visual analog scales are reliable tools to measure chronic spontaneous urticaria disease activity and can be incorporated into mobile health apps.
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose ...